My opinion is that many brokerages don't allow their retail clients to trade pinks for their protection. I'm sure non-retail investors without covenants against buying pink sheets would be able to trade NNLX if they wanted to.
Ameritrade will allow retail investors to trade NNLX.
Ironically, the illiquidity of NNLX is due to the strength of its shareholders regardless of whether this strength is defined by belief of eventual success or fear of realizing tremendous losses on their investment. LOL! I bet this statement kicked the hornets nest of those sour on this Company.
Let's say the government Contractor turns out to be Battelle as some have speculated. I've posted a couple links showing their deep ties with the CDC w.r.t. viruses and vaccines. If they were to put out the news we're hoping for linking Nanologix to them, this will drive demand for NNLX. Initially, there will be wild swings as the market tries to figure out how to accurately price NNLX, but the SP and trading action will get there, wherever there may be.
Let's say there is no big PR from them linking to Nanologix and the only update we get is from the CEO. Well, SP action may not be as exciting and it may take longer for the market to find a more accurate valuation, but it'll get there eventually. Especially when we find out the Company actually has a revenue stream in potentially $millions.
Doing some quick and very conservative back of the napkin calculations, if the Contractor sells 1,000,000 kits and royalties to the Company is $1 per kit (super cheap considering the prices of kits that are currently available), and assuming 160M shares outstanding, that's $0.00625 rev per share. SP of $0.05 is 8x this rev.
This is for just one application (covid-19). A few weeks ago, experts were saying we needed to be testing 100k people every day. By the time this pandemic is under control, it could be several million kits that the Company collects royalties on.
Plus this revenue will help fund the launch of new N-Assay applications and SEC reporting to bump NNLX to the OTCBB. But may not be necessary if the Company is bought up <-- This is my biggest hope!
Ameritrade will allow retail investors to trade NNLX.
Ironically, the illiquidity of NNLX is due to the strength of its shareholders regardless of whether this strength is defined by belief of eventual success or fear of realizing tremendous losses on their investment. LOL! I bet this statement kicked the hornets nest of those sour on this Company.
Let's say the government Contractor turns out to be Battelle as some have speculated. I've posted a couple links showing their deep ties with the CDC w.r.t. viruses and vaccines. If they were to put out the news we're hoping for linking Nanologix to them, this will drive demand for NNLX. Initially, there will be wild swings as the market tries to figure out how to accurately price NNLX, but the SP and trading action will get there, wherever there may be.
Let's say there is no big PR from them linking to Nanologix and the only update we get is from the CEO. Well, SP action may not be as exciting and it may take longer for the market to find a more accurate valuation, but it'll get there eventually. Especially when we find out the Company actually has a revenue stream in potentially $millions.
Doing some quick and very conservative back of the napkin calculations, if the Contractor sells 1,000,000 kits and royalties to the Company is $1 per kit (super cheap considering the prices of kits that are currently available), and assuming 160M shares outstanding, that's $0.00625 rev per share. SP of $0.05 is 8x this rev.
This is for just one application (covid-19). A few weeks ago, experts were saying we needed to be testing 100k people every day. By the time this pandemic is under control, it could be several million kits that the Company collects royalties on.
Plus this revenue will help fund the launch of new N-Assay applications and SEC reporting to bump NNLX to the OTCBB. But may not be necessary if the Company is bought up <-- This is my biggest hope!
2
1
